Wave Life Sciences’ obesity program faced renewed investor pressure after early clinical readouts from its first-in-human Inlight trial showed limited weight impact. The company reported a small body-weight decrease over six months while evaluating WVE-007, an INHBE-targeted GalNAc-siRNA, after investors had reacted to dose-related concerns earlier in the program.